Verrica Pharmaceuticals Doses First U.S. and Japanese Patient in COVE-3 Phase 3 Trial
VRCA•Verrica Pharmaceuticals dosed the first U.S. patient in the COVE-3 pivotal Phase 3 trial of YCANTH (VP-102) for common warts, while partner Torii Pharmaceutical dosed the first Japanese subject last week. Verrica retains global ex-Japan rights and aims to address a 22 million-patient U.S. market with no approved therapies.
1. COVE-3 Pivotal Phase 3 Trial Launch
Verrica initiated dosing of the first U.S. patient in its second pivotal Phase 3 study (COVE-3) evaluating YCANTH (VP-102) for common warts, following Torii Pharmaceutical's dosing of the first Japanese subject last week. The double-blind, randomized, vehicle-controlled trial applies treatments every 21 days for up to four applications in patients aged two years and older across U.S. and Japan sites.
2. Partnership and Funding Structure
Under the global collaboration, Torii will cover the first $40 million of trial costs (approximately 90% of the current budget) while Verrica will fund remaining expenses via future milestones and royalties. Verrica retains global rights outside Japan and intends to seek U.S. approval based on combined Phase 3 data while Torii pursues approval in Japan.
3. Market Opportunity and Unmet Need
With an estimated 22 million U.S. patients and no FDA-approved wart therapies, YCANTH targets a significant dermatology market potentially worth billions of dollars. Verrica anticipates commercial synergies with its existing molluscum contagiosum treatment and projects high demand among pediatric and adult patients.
